Literature DB >> 10634383

Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer?

A F Cailleux1, E Baudin, J P Travagli, M Ricard, M Schlumberger.   

Abstract

A diagnostic iodine-131 (131I) total body scan (TBS) is usually recommended 6 to 12 months after thyroid ablation for differentiated thyroid carcinoma. Its usefulness was evaluated in 256 consecutive patients treated and followed up at the Institut Gustave Roussy for papillary (n = 200), well differentiated (n = 27), or poorly differentiated (n = 29) follicular thyroid carcinomas. All patients underwent a near-total or total thyroidectomy and 131I ablation with 3.7 GBq (100 mCi). No TBS was performed before 131I ablation. The TBS performed after the administration of 131I to destroy the thyroid remnants showed uptake (<2%) limited to the thyroid bed. A diagnostic 131I-TBS was obtained after withdrawal of T4 treatment, with either 74 MBq (2 mCi; n = 82) or 185 MBq (5 mCi; n = 174), 6 to 12 months after initial treatment, with serum thyroglobulin (Tg) determination. No interference in the Tg assay was found in these 256 patients. Uptake in the thyroid bed was not detected (total ablation) in 236 patients, was visible but too low to be measured in 19 patients, and attained 1% in only 1 patient. No uptake was found outside the thyroid bed. The serum Tg level, once thyroid hormone treatment had been withdrawn, was below 1 ng/mL in 210 patients, ranged from 1-10 ng/mL in 31 patients, and was above 10 ng/mL in 15 patients. A 131I-TBS performed with 3.7 GBq in nine patients with a Tg level above 10 ng/mL, showed foci of uptake outside the thyroid bed in three patients; lung metastases were demonstrated by a CT scan in another patient, and palpable lymph node metastases were found in one patient. In conclusion, a diagnostic 131I-TBS with 74-185 MBq performed 1 yr after thyroid ablation demonstrated no abnormal uptake; it did not correlate with results of Tg determination and only confirmed the completeness of thyroid ablation. The serum Tg level obtained after withdrawal of T4 treatment permits the selection of patients with a Tg level exceeding 10 ng/mL, for scanning with 3.7 GBq (100 mCi).

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10634383     DOI: 10.1210/jcem.85.1.6310

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  35 in total

Review 1.  Papillary thyroid cancer: medical management and follow-up.

Authors:  Richard T Kloos
Journal:  Curr Treat Options Oncol       Date:  2005-07

2.  Robotic thyroidectomy by bilateral axillo-breast approach: review of 1,026 cases and surgical completeness.

Authors:  Kyu Eun Lee; Eunyoung Kim; Do Hoon Koo; June Young Choi; Kyu Hyung Kim; Yeo-Kyu Youn
Journal:  Surg Endosc       Date:  2013-02-23       Impact factor: 4.584

Review 3.  Advances in the follow-up of differentiated or medullary thyroid cancer.

Authors:  Rossella Elisei; Aldo Pinchera
Journal:  Nat Rev Endocrinol       Date:  2012-04-03       Impact factor: 43.330

4.  Radioactive iodine activities for postsurgical thyroid ablation: the lower the better.

Authors:  Furio Pacini
Journal:  Eur Thyroid J       Date:  2013-01

Review 5.  Papillary thyroid cancer.

Authors:  Nadine R Caron; Orlo H Clark
Journal:  Curr Treat Options Oncol       Date:  2006-07

6.  Stimulated Serum Thyroglobulin Level at the Time of First Dose of Radioactive Iodine Therapy Is the Most Predictive Factor for Therapeutic Failure in Patients With Papillary Thyroid Carcinoma.

Authors:  Hee Jeong Park; Geum-Cheol Jeong; Seong Young Kwon; Jung-Joon Min; Hee-Seung Bom; Ki Seong Park; Sang-Geon Cho; Sae-Ryung Kang; Jahae Kim; Ho-Chun Song; Ari Chong; Su Woong Yoo
Journal:  Nucl Med Mol Imaging       Date:  2014-06-28

7.  Prognostic value of an increase in the serum thyroglobulin level at the time of the first ablative radioiodine treatment in patients with differentiated thyroid cancer.

Authors:  Marie-Odile Bernier; Olivier Morel; Patrice Rodien; Jean-Pierre Muratet; Philippe Giraud; Vincent Rohmer; Christian Jeanguillaume; Jean-Claude Bigorgne; Pierre Jallet
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-08-26       Impact factor: 9.236

8.  Effects of low-dose and high-dose postoperative radioiodine therapy on the clinical outcome in patients with small differentiated thyroid cancer having microscopic extrathyroidal extension.

Authors:  Ji Min Han; Won Gu Kim; Tae Yong Kim; Min Ji Jeon; Jin-Sook Ryu; Dong Eun Song; Suck Joon Hong; Young Kee Shong; Won Bae Kim
Journal:  Thyroid       Date:  2014-01-29       Impact factor: 6.568

9.  Limited adequacy of thyroid cancer patient follow-up at a Canadian tertiary care centre.

Authors:  Elaine Lam; Scott S Strugnell; Chris Bajdik; Daniel Holmes; Sam M Wiseman
Journal:  Can J Surg       Date:  2013-12       Impact factor: 2.089

10.  Clinical significance of observation without repeated radioiodine therapy in differentiated thyroid carcinoma patients with positive surveillance whole-body scans and negative thyroglobulin.

Authors:  Dong-Jun Lim; Joo Hyun O; Min-Hee Kim; Ji-Hyun Kim; Hyuk-Sang Kwon; Sung-Hoon Kim; Moo-Il Kang; Bong-Yun Cha; Kwang-Woo Lee; Ho-Young Son
Journal:  Korean J Intern Med       Date:  2010-11-27       Impact factor: 2.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.